OptiBiotix Health (GB:OPTI) has released an update.
OptiBiotix Health PLC is experiencing robust sales growth in H1 2024, with a strategic focus on expanding its partner network in the lucrative US and Asian markets, boosting direct-to-consumer e-commerce sales, and increasing gross profit margins through finished product sales. The company has secured significant orders, such as the £175K initial order from Dr Morepen in India, and anticipates a transformative impact from new partnerships and market entries. Investments in e-commerce and successful product launches, like LeanBiome in MuscleTech, are expected to drive continued growth and profitability.
For further insights into GB:OPTI stock, check out TipRanks’ Stock Analysis page.
